Related Experiment Video

Updated: Oct 16, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers

Yuta Adachi1, Ryo Kimura1, Kentaro Hirade1

  • 1Division of Molecular Therapeutics, Aichi Cancer Center Research Institute, Nagoya 464-8681, Japan.

Cancers
|October 23, 2021
PubMed

Insights

Activating KRAS mutations drive cancer, but some tumors become KRAS-independent. Understanding bypass networks is crucial for treating resistant cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Activating KRAS mutations are found in 25% of human cancers, driving proliferation and suppressing apoptosis.
  • Mutant KRAS promotes metabolic deregulation and alters the tumor microenvironment, but cancer cells can develop KRAS independence.

Purpose of the Study:

  • To investigate the mechanisms of KRAS independence in cancer cells.
  • To identify pathways and genetic alterations that confer KRAS independence.
  • To understand the therapeutic implications of KRAS dependency and independency.

Main Methods:

  • Review of molecular mechanisms underlying KRAS signaling and bypass networks.
  • Analysis of genetic co-mutations (e.g., LKB1, KEAP1, NRF2) and pathway activations (YAP1, RSK-mTOR) associated with KRAS independency.
  • Exploration of metabolic reprogramming (e.g., glutaminolysis) and epithelial-to-mesenchymal transition (EMT) in KRAS-independent cancers.

Main Results:

  • KRAS-independent cancer cells activate bypass signaling networks (YAP1, RSK-mTOR) and exhibit co-mutations in LKB1, KEAP1, and NRF2.
  • Metabolic reprogramming, including increased glutaminolysis, and EMT are linked to KRAS autonomy.
  • KRAS independency contributes to primary and acquired resistance to KRAS-targeted therapies.

Conclusions:

  • KRAS dependency varies among KRAS-mutant cancers, influencing therapeutic response.
  • Understanding bypass signaling is essential for developing effective treatments for KRAS-independent tumors.
  • Targeting KRAS-independent cancer vulnerabilities requires further research into alternative survival pathways.
Keywords:
EMTKRASRSKYAP1autonomydependencymetabolic reprogramming

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.2K
Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells09:20

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells

Published on: July 6, 2021

2.5K

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.1K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.4K